GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calidi Biotherapeutics Inc (AMEX:CLDI) » Definitions » Debt-to-Revenue

Calidi Biotherapeutics (Calidi Biotherapeutics) Debt-to-Revenue : N/A (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Calidi Biotherapeutics Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Calidi Biotherapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $5.39 Mil. Calidi Biotherapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $6.33 Mil. Calidi Biotherapeutics's annualized Revenue for the quarter that ended in Mar. 2024 was $0.00 Mil.


Calidi Biotherapeutics Debt-to-Revenue Historical Data

The historical data trend for Calidi Biotherapeutics's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calidi Biotherapeutics Debt-to-Revenue Chart

Calidi Biotherapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
N/A 11.54 133.07 N/A

Calidi Biotherapeutics Quarterly Data
Dec20 Sep21 Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of Calidi Biotherapeutics's Debt-to-Revenue

For the Biotechnology subindustry, Calidi Biotherapeutics's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Calidi Biotherapeutics's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Calidi Biotherapeutics's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Calidi Biotherapeutics's Debt-to-Revenue falls into.



Calidi Biotherapeutics Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Calidi Biotherapeutics's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.923 + 5.313) / N/A
=N/A

Calidi Biotherapeutics's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(5.385 + 6.328) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


Calidi Biotherapeutics Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Calidi Biotherapeutics's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Calidi Biotherapeutics (Calidi Biotherapeutics) Business Description

Traded in Other Exchanges
N/A
Address
11011 North Torrey Pines Road, Suite 200, La Jolla, CA, USA, 92037
Calidi Biotherapeutics Inc is a clinical stage immuno-oncology company pioneering the development and commercialization of novel, potent and efficient stem cell-based platforms for delivery and potentiation of oncolytic viruses for the treatment of cancer.

Calidi Biotherapeutics (Calidi Biotherapeutics) Headlines